Prosecution Insights
Last updated: November 15, 2026
Application No. 18/011,688

PROSTHETIC TRANSCATHETER HEART VALVE (THV) SYSTEM

Non-Final OA §112
Filed
Dec 20, 2023
Priority
Oct 18, 2021 — IN 202121047196 +1 more
Examiner
ALEMAN, SARAH WEBB
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Meril Life Sciences Pvt Ltd.
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
86%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
376 granted / 603 resolved
-7.6% vs TC avg
Strong +24% interview lift
Without
With
+23.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
34 currently pending
Career history
640
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claims 22-25 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 9/30/2026. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites the limitation "that comprises interlaced octagonal cells creating alternate sequence of diamond shaped cells or rhombus bodies at each junction" in lines 33-34. There is insufficient antecedent basis for the term “junction” in the claim, so it is unclear whether the term “junction” is referring to the location of a link, etc. Additionally appears that the phrase “creating alternate sequence” is missing a term and should be changed to “that creates an alternating sequence”. Claims 2-20 depends from claim 1 and are indefinite for the same reasons. Claim 21 recites the limitation "that comprises interlaced octagonal cells creating alternate sequence of diamond shaped cells or rhombus bodies at each junction" in lines 23-24. There is insufficient antecedent basis for the term “junction” in the claim, so it is unclear whether the term “junction” is referring to the location of a link, etc. Additionally appears that the phrase “creating alternate sequence” is missing a term and should be changed to “that creates an alternating sequence”. Allowable Subject Matter Claims 1-21 are free of prior art rejections and would be allowable if amended to overcome the 112 rejections. As allowable subject matter has been indicated, applicant's reply must either comply with all formal requirements or specifically traverse each requirement not complied with. See 37 CFR 1.111(b) and MPEP § 707.07(a). The following is a statement of reasons for the indication of allowable subject matter: Prior art discloses various stent designs having hexagonal and/or octagonal cells, and links between undulating rows having openings. USPAP 2020/0352709 (Gurovich et al.) discloses a stent with rows of hexagonal cells and some links having an opening (62) (Fig. 11). USPAP 2018/0325660 discloses a stent having hexagonal cells and links (1314) having openings (1336) (Fig. 21). USPAP 2012/0029619 discloses a stent wherein the struts define a plurality of openings, wherein the openings are for drug delivery. USPAP 2012/0016458 discloses the concept of a stent frame defining a diamond shaped opening (see 229 in Figure 6a) but the opening is at a peak/valley of an undulating row and not defined by a link. USPAP 2009/0132027 discloses a stent design having rows of hexagonal cells alternating with a row of diamond shaped cells in sequence with hexagonal cells (Fig. 4). Prior art fails to disclose or render obvious the particular arrangement of interlaced octagonal cells with an alternating sequence of links defining a rhombus body or diamond shaped opening, in combination with other claimed elements. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAH WEBB ALEMAN whose telephone number is (571)272-5749. The examiner can normally be reached M, Tu, Th, Fr 9am - 3pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melanie Tyson can be reached at 571-272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARAH W ALEMAN/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Dec 20, 2023
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766000
HEART VALVE REPAIR
4y 8m to grant Granted Oct 20, 2026
Patent 12751710
DEVICES AND METHODS FOR OCCLUDING OR PROMOTING FLUID FLOW
3y 5m to grant Granted Oct 06, 2026
Patent 12740880
DEVICES AND METHODS FOR TREATING BRANCHING BLOOD VESSELS
4y 0m to grant Granted Sep 22, 2026
Patent 12734056
MEDICAL TUBULAR BODY DELIVERING DEVICE
4y 3m to grant Granted Sep 15, 2026
Patent 12714586
BIFURCATED BALLOON EXPANDABLE STENT ASSEMBLY
4y 1m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
86%
With Interview (+23.7%)
Low
PTA Risk
Based on 603 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month